Plaquenil: Advanced Hydroxychloroquine for Autoimmune Management
Plaquenil
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.00 | $50.00 (0%) | 🛒 Add to cart |
| 20 | $4.00 | $100.00 $80.00 (20%) | 🛒 Add to cart |
| 30 | $3.67 | $150.00 $110.00 (27%) | 🛒 Add to cart |
| 60 | $3.50 | $300.00 $210.00 (30%) | 🛒 Add to cart |
| 90 | $3.33 | $450.00 $300.00 (33%) | 🛒 Add to cart |
| 120 | $2.92 | $600.00 $350.00 (42%) | 🛒 Add to cart |
| 180 | $2.78 | $900.00 $500.00 (44%) | 🛒 Add to cart |
| 270 | $2.59 | $1350.00 $700.00 (48%) | 🛒 Add to cart |
| 360 | $2.39
Best per pill | $1800.00 $860.00 (52%) | 🛒 Add to cart |
| Product dosage: 400mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $7.00 | $70.00 (0%) | 🛒 Add to cart |
| 20 | $6.00 | $140.00 $120.00 (14%) | 🛒 Add to cart |
| 30 | $5.67 | $210.00 $170.00 (19%) | 🛒 Add to cart |
| 60 | $5.33 | $420.00 $320.00 (24%) | 🛒 Add to cart |
| 90 | $5.00 | $630.00 $450.00 (29%) | 🛒 Add to cart |
| 120 | $4.58 | $840.00 $550.00 (35%) | 🛒 Add to cart |
| 180 | $4.44 | $1260.00 $800.00 (37%) | 🛒 Add to cart |
| 270 | $4.26 | $1890.00 $1150.00 (39%) | 🛒 Add to cart |
| 360 | $4.03
Best per pill | $2520.00 $1450.00 (42%) | 🛒 Add to cart |
Plaquenil (hydroxychloroquine sulfate) is a disease-modifying antirheumatic drug (DMARD) widely prescribed for the management of autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. Its immunomodulatory and anti-inflammatory properties help reduce disease activity, prevent flares, and protect against long-term organ damage. By interfering with antigen processing and cytokine production, Plaquenil offers a well-tolerated, foundational therapy option for patients requiring sustained immunosuppression with a favorable safety profile relative to other agents.
Features
- Contains hydroxychloroquine sulfate as the active pharmaceutical ingredient
- Available in 200 mg film-coated tablets
- Oral administration with high bioavailability
- Long half-life allowing for once or twice daily dosing
- Demonstrated anti-inflammatory, immunomodulatory, and antimalarial properties
Benefits
- Reduces frequency and severity of disease flares in autoimmune conditions
- Helps prevent joint damage and deformity in rheumatoid arthritis
- Decreases risk of lupus-related organ complications, including renal and cutaneous involvement
- May offer protective cardiovascular and lipid-modulating effects
- Generally well-tolerated with a lower risk of immunosuppression compared to biologics
- Can be used long-term with appropriate monitoring
Common use
Plaquenil is indicated for the treatment of uncomplicated malaria, rheumatoid arthritis, and systemic lupus erythematosus. It is also used off-label for other autoimmune disorders such as Sjögren’s syndrome, discoid lupus erythematosus, and porphyria cutanea tarda. In rheumatology, it is often employed as a first-line DMARD, either as monotherapy or in combination with other agents like methotrexate.
Dosage and direction
For rheumatoid arthritis and lupus erythematosus, the recommended initial dose is 400–600 mg daily (given as a single or divided dose). After achieving optimal response, the dose is often reduced to a maintenance level of 200–400 mg daily. Dosing should be based on ideal body weight and renal function. Tablets should be taken with food or milk to minimize gastrointestinal upset. Regular ophthalmologic examinations are mandatory due to the risk of retinopathy.
Precautions
Patients should be advised that therapeutic effects may not be apparent for several weeks to months. Regular monitoring of complete blood count, liver function, and renal function is recommended. Use with caution in patients with hepatic or renal impairment, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or psoriasis. Pregnancy and breastfeeding require careful risk-benefit assessment under specialist supervision.
Contraindications
Plaquenil is contraindicated in patients with known hypersensitivity to hydroxychloroquine or 4-aminoquinoline compounds. It should not be used in those with pre-existing macular changes or visual field defects. Concomitant use with other drugs known to cause retinal toxicity is not recommended.
Possible side effect
Common adverse reactions include nausea, abdominal cramps, diarrhea, headache, and skin rash. Less frequently, patients may experience mood changes, hair bleaching, or neuromuscular weakness. The most serious potential side effect is irreversible retinopathy, which is dose- and duration-dependent. Other rare but serious reactions include cardiomyopathy, hematologic toxicity, and severe cutaneous reactions.
Drug interaction
Plaquenil may enhance the effects of digoxin and insulin. Concomitant use with drugs that prolong QT interval (e.g., macrolides, antipsychotics) should be avoided. Antacids and kaolin may reduce absorption. It may potentiate the toxicity of other hepatotoxic or myelosuppressive agents. Caution is advised when co-administering with CYP450 inhibitors or inducers.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Patients should maintain regular dosing schedules to ensure consistent therapeutic levels.
Overdose
Overdose can be fatal and may present with headache, visual disturbances, cardiovascular collapse, convulsions, and hypokalemia. Immediate medical attention is required. Treatment is supportive and may include gastric lavage, activated charcoal, and respiratory and cardiac monitoring.
Storage
Store at room temperature (15–30°C) in a dry place, protected from light. Keep in the original container with the lid tightly closed. Do not use if tablets show signs of discoloration or deterioration. Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Dosage and treatment decisions must be made by a qualified healthcare provider based on individual patient characteristics. Always follow the prescribing information provided with the medication.
Reviews
Clinical studies and long-term observational data support the efficacy and safety of Plaquenil in autoimmune management. Many patients report improved quality of life, reduced pain, and decreased steroid dependence. However, adherence to monitoring protocols is essential to mitigate retinal toxicity risks. Patient experiences vary, with some noting gastrointestinal tolerability issues during initial treatment phases.